Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 6/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962259 | 0.82 | PYCR1 (0.53) | PYCR1MEN1LMNAKMT2ATAAR1 | |
| SCHEMBL1472497 | 0.82 | NR1I2 (0.42) | PYCR1HRH3 | |
| SCHEMBL4632355 | 0.82 | PYCR1 (0.41) | PYCR1HRH3TAAR1 | |
| SCHEMBL23032284 | 0.82 | ALDH1A1 (0.52) | PYCR1CYP2C19LMNACYP1A2 | |
| SCHEMBL16312619 | 0.80 | PYCR1 (0.65) | PYCR1NPSR1CYP2C19IDO1HRH3 | |
| Hydrochloric Acid SCHEMBL25237515 | 0.80 | ALDH1A1 (0.52) | PYCR1CYP2C19LMNACYP1A2 | |
| SCHEMBL1009445 | 0.78 | PYCR1 (0.38) | PYCR1HRH3LMNA | |
| SCHEMBL17540309 | 0.78 | PYCR1 (0.41) | PYCR1HRH3KCNH2 | |
| SCHEMBL4631973 | 0.78 | CYP2A6 (0.46) | PYCR1IDO1HRH3CYP2A6 | |
| SCHEMBL22013587 | 0.75 | CA2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915258-B2 | Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one derivatives, preparation thereof and therapeutic use of the same | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | disclosed |
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | DHFR, DPYD, QDPR | PYCR1 53/4885NPSR1 577/4885CYP2C19 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.